Arix Bioscience PLC
LSE:ARIX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Arix Bioscience PLC
Cash from Operating Activities
Arix Bioscience PLC
Cash from Operating Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Arix Bioscience PLC
LSE:ARIX
|
Cash from Operating Activities
-£4.6m
|
CAGR 3-Years
18%
|
CAGR 5-Years
12%
|
CAGR 10-Years
N/A
|
|
|
Janus Henderson Group PLC
NYSE:JHG
|
Cash from Operating Activities
$719.5m
|
CAGR 3-Years
15%
|
CAGR 5-Years
2%
|
CAGR 10-Years
N/A
|
|
|
3i Group PLC
LSE:III
|
Cash from Operating Activities
£830m
|
CAGR 3-Years
24%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
9%
|
|
|
Schroders PLC
LSE:SDR
|
Cash from Operating Activities
£914.4m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
2%
|
CAGR 10-Years
N/A
|
|
|
N
|
Ninety One PLC
LSE:N91
|
Cash from Operating Activities
£211.9m
|
CAGR 3-Years
-30%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
N/A
|
|
|
A
|
Allfunds Group PLC
AEX:ALLFG
|
Cash from Operating Activities
€228.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-23%
|
CAGR 10-Years
N/A
|
|
Arix Bioscience PLC
Glance View
Arix Bioscience Plc is a global venture capital company. The firm is a holding company that is focused on generating value from the development and commercialization of technologies and discoveries. The firm's principal activity is to source, finance and develop healthcare and life science businesses across the world. The firm focuses on acquiring interests in, and provide operational oversight to, healthcare and life science businesses with which it partners in the healthcare and life science sector. The Company’s portfolio includes Harpoon Therapeutics, Inc. (HARP), Artios Pharma Ltd (Artios), Aura Biosciences Inc (Aura), LogicBio Therapeutics, Inc. (LOGC). The firm's subsidiaries include Depixus SAS (EUR), Quench Bio, Inc., Stipe Therapeutics Aps and Twelve Bio Aps.
See Also
What is Arix Bioscience PLC's Cash from Operating Activities?
Cash from Operating Activities
-4.6m
GBP
Based on the financial report for Dec 31, 2022, Arix Bioscience PLC's Cash from Operating Activities amounts to -4.6m GBP.
What is Arix Bioscience PLC's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
12%
Over the last year, the Cash from Operating Activities growth was 35%. The average annual Cash from Operating Activities growth rates for Arix Bioscience PLC have been 18% over the past three years , 12% over the past five years .
